These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26898158)

  • 1. Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
    Rosenthal ES; Kottilil S; Polis MA
    Expert Opin Pharmacother; 2016; 17(5):743-9. PubMed ID: 26898158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection.
    Havens JP; Regan NN; Bares SH
    Am J Case Rep; 2020 Jun; 21():e923326. PubMed ID: 32493896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
    Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Henry L; Hunt S
    J Viral Hepat; 2016 Nov; 23(11):857-865. PubMed ID: 27291391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
    Kumari R; Nguyen MH
    Expert Opin Pharmacother; 2015 Apr; 16(5):739-48. PubMed ID: 25676581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population.
    Banga J; Nizami S; Slim J; Nagarakanti S; Portilla M; Swaminathan S
    Medicine (Baltimore); 2020 Mar; 99(11):e19140. PubMed ID: 32176039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
    Sollima S; Antinori S; Torre A; Binda F; Giacomelli A; Milazzo L
    Int J STD AIDS; 2017 Jul; 28(8):838-840. PubMed ID: 28632109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
    Naggie S; Cooper C; Saag M; Workowski K; Ruane P; Towner WJ; Marks K; Luetkemeyer A; Baden RP; Sax PE; Gane E; Santana-Bagur J; Stamm LM; Yang JC; German P; Dvory-Sobol H; Ni L; Pang PS; McHutchison JG; Stedman CA; Morales-Ramirez JO; Bräu N; Jayaweera D; Colson AE; Tebas P; Wong DK; Dieterich D; Sulkowski M;
    N Engl J Med; 2015 Aug; 373(8):705-13. PubMed ID: 26196665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T; Jiang X; Chen Y; Song Y
    Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
    Keating GM
    Drugs; 2015 Apr; 75(6):675-85. PubMed ID: 25837989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.
    Corma-Gómez A; Macías J; Merino Muñoz D; Téllez F; Granados R; Morano LE; De Los Santos Gil I; Vera-Méndez FJ; Collado A; Palacios R; Pineda JA
    J Infect; 2019 Jul; 79(1):30-35. PubMed ID: 31100364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
    Scott LJ
    Drugs; 2018 Feb; 78(2):245-256. PubMed ID: 29380288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    J Gastroenterol; 2017 Jul; 52(7):845-854. PubMed ID: 27913920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
    Sevastianova K; Dean J; Bannan C; Coghlan M; Farrell G; Murray C; De Gascun CF; Bergin C
    J Clin Virol; 2016 Sep; 82():66-69. PubMed ID: 27454231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
    Ingiliz P; Christensen S; Kimhofer T; Hueppe D; Lutz T; Schewe K; Busch H; Schmutz G; Wehmeyer MH; Boesecke C; Simon KG; Berger F; Rockstroh JK; Schulze zur Wiesch J; Baumgarten A; Mauss S
    Clin Infect Dis; 2016 Nov; 63(10):1320-1324. PubMed ID: 27535952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
    Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
    Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
    Cooper C; Naggie S; Saag M; Yang JC; Stamm LM; Dvory-Sobol H; Han L; Pang PS; McHutchison JG; Dieterich D; Sulkowski M
    Clin Infect Dis; 2016 Aug; 63(4):528-31. PubMed ID: 27225242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection.
    Huffman V; Andrade DC; Sherman E; Niu J; Eckardt PA
    Am J Health Syst Pharm; 2021 Jan; 78(1):36-40. PubMed ID: 33037429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.